CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

Trial Details

NCT ID
NCT06834282
Phase
PHASE1
Sponsor
CERo Therapeutics Holdings, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CER-1236
  • Cyclophosphamide
  • Fludarabine
  • Mesna
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • Denver, Colorado, United States|39.73915,-104.9847
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Patients need to have a confirmed diagnosis of de novo or secondary AML, or myelodysplastic syndrome (MDS)/AML with 10% to 19% blasts, per the Inte…
  • Absolute lymphocyte count \>0.3 x 109/L prior to apheresis.
  • Eastern cooperative oncology group (ECOG) performance status 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →